1995 Volume 43 Issue Supplement4 Pages 111-116
We performed bacteriological and clinical studies on cefluprenam (CFLP), a new parenternal cephalosporin, in urinary tract infections with the following results.
1. The antibacterial activity of CFLP against clinical isolates from patients with urinary tract infections was compared with that of ceftazidime, cefepime, flomoxef and imipenem, Against Staphylococcus aureus and Enterococcus faecalis, antibacterial activity of CFLP was markedly superior to other cephalosporins. And against gram-negative bacteria including P.aeruginosa, that was similar to that of imipenem.
2. Fourteen patients with complicated urinary tract infections were treated with 0.5g or 1.0g of CFLP twice a day for 5 days. According to the criteria proposed by the Japan UTI Comittee, the overall clinical efficacy of CFLP was 80%. Bacteriologically, 16 of 18 strains (89%) were eradicated. Neither adverse reactions nor abnormal laboratory findings were observed.
We concluded CFLP was a useful drug in the treatnent of urinary tract infections.
